TOP TEN perturbations for 1552304_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552304_at
Selected probe(set): 1552306_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552304_at (1552306_at) across 6540 perturbations tested by GENEVESTIGATOR:

LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):-2.2865238
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):2.2784052
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)

Relative Expression (log2-ratio):-2.2338266
Number of Samples:20 / 18
Experimental atopic dermatitis study 12 (lesional; adults)
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (lesional; children)
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):2.1121254
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

OPM-1 / MM1.S

Relative Expression (log2-ratio):-2.0553026
Number of Samples:4 / 4
Experimental OPM-1
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code:
Control MM1.S
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code:

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.0127792
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

MCF-7.5C / MCF-7

Relative Expression (log2-ratio):1.998064
Number of Samples:3 / 4
Experimental MCF-7.5C
Human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Long-term estrogen deprived breast cancer cells, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. Parental cell line:: MCF-7 Synonyms:MCF-7 clone 5C; 5C; MCF-7:5C Cellosaurus code:
Control MCF-7
Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code:

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):1.9545183
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-1.9463806
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

resorcinol study 1 (48h) / vehicle (EtOH) treated HepG2 cell sample

Relative Expression (log2-ratio):1.9224081
Number of Samples:3 / 6
Experimental resorcinol study 1 (48h)
HepG2 cells exposed to 2mM resorcinol in EtOH solvent for 48 hours. ATC code:,
Control vehicle (EtOH) treated HepG2 cell sample
HepG2 cells exposed to EtOH solvent for 48 hours.